Herriot Tabuteau, Axsome CEO
June 14, 2023 10:34 AM EDTUpdated 10:53 AM
R&D

Ax­some re­ports de­lay to PhI­II nar­colep­sy study, un­veils peak sales es­ti­mates on its drugs

Kyle LaHucik

Senior Reporter

Ax­some Ther­a­peu­tics ad­just­ed the time­line of a Phase III tri­al for an ex-Pfiz­er drug that it ex­pects to mar­ket for nar­colep­sy by 2025.

The New …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times